AVIDA The Vidaza® (Azacitidine) Patient Registry

Celgene

Status: Completed

Conditions: Myelodysplastic Syndromes

Treatments: Drug: Azacitidine

Study type: Observational

Funder types: Industry

Identifiers

NCT00481273

AVIDA

Details and patient eligibility

About

This registry is a prospective, multi-center, observational study compiling data on the natural history and management of patients receiving Vidaza, and will provide unique insights into the management of myelodysplastic syndromes (MDS) and other hematological disorders and the impact of these disorders on patients.

Enrollment: 479 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient who is deemed appropriate for treatment with Vidaza® by his or her clinician, but who has not already started receiving Vidaza® treatment.
• Patient who is able to read and speak English.
• Patient who is willing and able to provide informed consent.
• Patient who agrees to complete patient assessment questionnaires.

Exclusion criteria

• Patients who are currently being treated with Vidaza®.
• Patients who are concurrently participating in a clinical trial.
• Patients unwilling or unable to complete the baseline and follow-up questionnaires.
• Patients who are deemed inappropriate for treatment with Vidaza®.